Parkinson's disease other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (9 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
'''PET scan''': In [[PET scan]] we can see that the uptake of [18F]-flurodopa tracer in reduce in the [[Caudate nucleus|caudate]] and [[putamen]] in [[Parkinson's disease|PD]] patients. | |||
'''DaTscan''': This technique can help us differentiate healthy individuals or patients with [[essential tremor]] from diseases with nigrostriatal degeneration ([[Parkinson's disease|PD]], [[Multiple system atrophy|MSA]], [[Progressive supranuclear palsy|PSP]], and cortical degeneration). | |||
'''Sonography''': In [[sonography]] of [[Parkinson's disease|PD]] patient’s [[brain]] we can see hyperechogenicity of the [[STN]]. | |||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
* '''PET scan''': In [[PET scan]] we can see that the uptake of [18F]-flurodopa tracer in reduce in the [[Caudate nucleus|caudate]] and [[putamen]] in [[Parkinson's disease|PD]] patients.<ref name="pmid20669302">{{cite journal |vauthors=Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL |title=Typical cerebral metabolic patterns in neurodegenerative brain diseases |journal=Mov. Disord. |volume=25 |issue=14 |pages=2395–404 |date=October 2010 |pmid=20669302 |doi=10.1002/mds.23291 |url=}}</ref> | |||
[[Image:PET scan Parkinson's Disease.jpg|thumb|left|200px|18F PET scan shows decreased dopamine activity in the [[basal ganglia]], a pattern which aids in diagnosing Parkinson's disease.]] | [[Image:PET scan Parkinson's Disease.jpg|thumb|left|200px|18F PET scan shows decreased dopamine activity in the [[basal ganglia]], a pattern which aids in diagnosing Parkinson's disease.]] | ||
<br clear="left"/> | <br clear="left" /> | ||
* '''DaTscan''': This technique can help us differentiate healthy individuals or patients with [[essential tremor]] from diseases with nigrostriatal degeneration ([[Parkinson's disease|PD]], [[Multiple system atrophy|MSA]], [[Progressive supranuclear palsy|PSP]], and cortical degeneration).<ref name="pmid22014434">{{cite journal |vauthors=Stoessl AJ, Martin WW, McKeown MJ, Sossi V |title=Advances in imaging in Parkinson's disease |journal=Lancet Neurol |volume=10 |issue=11 |pages=987–1001 |date=November 2011 |pmid=22014434 |doi=10.1016/S1474-4422(11)70214-9 |url=}}</ref><ref name="pmid20019219">{{cite journal |vauthors=Kägi G, Bhatia KP, Tolosa E |title=The role of DAT-SPECT in movement disorders |journal=J. Neurol. Neurosurg. Psychiatry |volume=81 |issue=1 |pages=5–12 |date=January 2010 |pmid=20019219 |doi=10.1136/jnnp.2008.157370 |url=}}</ref> | |||
* '''Sonography''': In [[sonography]] of [[Parkinson's disease|PD]] patient’s [[brain]] we can see hyperechogenicity of the [[STN]].<ref name="pmid18394965">{{cite journal |vauthors=Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D |title=The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study |journal=Lancet Neurol |volume=7 |issue=5 |pages=417–24 |date=May 2008 |pmid=18394965 |doi=10.1016/S1474-4422(08)70067-X |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Latest revision as of 19:09, 28 November 2018
|
Parkinson's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parkinson's disease other imaging findings On the Web |
|
American Roentgen Ray Society Images of Parkinson's disease other imaging findings |
|
Risk calculators and risk factors for Parkinson's disease other imaging findings |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
PET scan: In PET scan we can see that the uptake of [18F]-flurodopa tracer in reduce in the caudate and putamen in PD patients.
DaTscan: This technique can help us differentiate healthy individuals or patients with essential tremor from diseases with nigrostriatal degeneration (PD, MSA, PSP, and cortical degeneration).
Sonography: In sonography of PD patient’s brain we can see hyperechogenicity of the STN.
Other Imaging Findings
- PET scan: In PET scan we can see that the uptake of [18F]-flurodopa tracer in reduce in the caudate and putamen in PD patients.[1]
- DaTscan: This technique can help us differentiate healthy individuals or patients with essential tremor from diseases with nigrostriatal degeneration (PD, MSA, PSP, and cortical degeneration).[2][3]
- Sonography: In sonography of PD patient’s brain we can see hyperechogenicity of the STN.[4]
References
- ↑ Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL (October 2010). "Typical cerebral metabolic patterns in neurodegenerative brain diseases". Mov. Disord. 25 (14): 2395–404. doi:10.1002/mds.23291. PMID 20669302.
- ↑ Stoessl AJ, Martin WW, McKeown MJ, Sossi V (November 2011). "Advances in imaging in Parkinson's disease". Lancet Neurol. 10 (11): 987–1001. doi:10.1016/S1474-4422(11)70214-9. PMID 22014434.
- ↑ Kägi G, Bhatia KP, Tolosa E (January 2010). "The role of DAT-SPECT in movement disorders". J. Neurol. Neurosurg. Psychiatry. 81 (1): 5–12. doi:10.1136/jnnp.2008.157370. PMID 20019219.
- ↑ Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (May 2008). "The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study". Lancet Neurol. 7 (5): 417–24. doi:10.1016/S1474-4422(08)70067-X. PMID 18394965.